Metabolites of arsenic and increased DNA damage of p53 gene in arsenic plant workers

Toxicology and Applied Pharmacology

Volumn 254, Issue 1, 2011, Pages 41-47

  Wen, Weihua ^a,b   Wen, Jinghua ^c   Lu, Lin ^a   Liu, Hua ^d   Yang, Jun ^a   Cheng, Huirong ^a   Che, Wangjun ^e   Li, Liang ^f   Zhang, Guanbei ^g  

^a YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c GUIZHOU UNIVERSITY OF FINANCE AND ECONOMICS   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e Kunming Center for Disease Control and Prevention   (China)

^f Honghe Zhou Center for Disease Control and Prevention   (China)

^g Yunnan Institute for Drug Abuse   (China)

Author keywords

Arsenic; Dimethylarsinic acid; Monomethylarsonic acid; Oxidative DNA damage; P53 gene; ROS

Indexed keywords

ARSENIC ACID; ARSENIC TRIOXIDE; METHANEARSONIC ACID; PROTEIN P53;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CHEMICAL INDUSTRY; CONTROLLED STUDY; DNA DAMAGE; EXON; HUMAN; INDUSTRIAL WORKER; MAJOR CLINICAL STUDY; METHYLATION; OCCUPATIONAL HAZARD; URINALYSIS;

ARSENIC; ARSENICALS; CACODYLIC ACID; CHEMICAL INDUSTRY; CREATININE; DNA DAMAGE; EXONS; GENES, P53; HUMANS; OCCUPATIONAL EXPOSURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79958013517     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.04.013     Document Type: Article

References (42)

1. Aihua Z., Hong F., Guanghong Y., Xueli P., Xianyao J., Xiaoxin H., Xuexin D., et al. Unventilated indoor coal-fired stoves in Guizhou Province, China: cellular and genetic damage in villagers exposed to arsenic in food and air. Environ. Health Perspect. 2007, 115(4):653-658.
2. Aposhian H.V., Gurzau E.S., Le X.C., Gurzau A., Healy S.M., Lu X., Ma M., et al. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 2000, 13:693-697.
3. Bargonetti J., Manfredi J.J. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002, 14:86-91.
4. Chin-Hsiao T. A review on environmental factors regulating arsenic methylation in humans. Toxicol. Appl. Pharmacol. 2009, 235:338-350.
5. Chiung-Wen H., Chih-Hong P., Yeou-Lih H., Ming-Tsang W., Louis W.C., Chien-Jen W., Mu-Rong C. Effects of arsenic exposure among semiconductor workers: a cautionary note on urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine. Free Radical Biol. Med. 2006, 40:1273-1278.
6. Cohen S.M., Arnold L.L., Eldan M., Lewis A.S., Beck B.D. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit. Rev. Toxicol. 2006, 36:99-133.
7. Colman M.S., Afshari C.A., Barrett J.C. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 2000, 462:179-188.
8. Crecelius E.A. Changes in the chemical speciation of arsenic following ingestion by man. Environ. Health Perspect. 1977, 19:147-150.
9. Dasheng L., Kanehisa M., Tatsuya T., Yuquan L. Formamidopyrimidine-DNA glycosylase enhances arsenic-induced DNA strand breaks in PHA-stimulated and unstimulated human lymphocytes. Environ. Health Perspect. 2001, 109:147-150.
10. Dawoon J., Youngeun C., Joel N.M., Richard T.D.G. The long amplicon quantitative PCR for DNA damage assay as a sensitive method of assessing DNA damage in the environmental model, Atlantic killifish (Fundulus heteroclitus). Comp. Biochem. Phys. C. 2009, 149(2009):182-186.
11. Fisher D.E. The p53 tumor suppressor: critical regulator of life and death in cancer. Apoptosis 2001, 6:7-15.
12. Hiroshi Y., Yoshito A., Katsumi Y., Guifan S., Jingbo P., Michael P.M. Evaluation of DNA damage in patients with arsenic poisoning: urinary 8-hydroxyguanine. Toxicol. Appl. Pharmacol. 2004, 198:291-296.
13. Jan A.S., Donald A.P., Terry W.F., James D. Effect ofDNA damage on PCR amplification efficiency with the relative threshold cycle method. Biochem. Biophys. Res. Commun. 2004, 323:823-830.
14. Jan A.S., Donald A.P., Terry W.F., James D. DNA damage reduces Taq DNA polymerase fidelity and PCR amplification efficiency. Biochem. Biophys. Res. Commun. 2007, 355:431-437.
15. Junko F., Yoshimi F., Tetsuro A., Takashi K., Toshihiro Y., Tamami M., Haruo T. Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol. Appl. Pharmacol. 2009, 234:41-46.
16. Junko F., Mikiko S., Toshihiro Y., Yoshiro K., Tetsuro A., Takashi K., Miki T., Takaya Y., Haruo T. Global analysis of genetic variation in human arsenic (+3 oxidation state) methyltransferase (AS3MT). Toxicol. Appl. Pharmacol. 2010, 243:292-299.
17. Kenzo Y., Koichi K., Mutsumi M., Yan A., Fumiyo T., Masayuki N., Mikio H., Shoji O. The role of active arsenic species produced by metabolic reduction of dimethylarsinic acid in genotoxicity and tumorigenesis. Toxicol. Appl. Pharmacol. 2004, 198:385-393.
18. Kirsi V. TP53 mutation in workers exposed to occupational carcinogens. Hum. mutat. 2003, 21:240-251.
19. Le X.C., Lu X., Ma M., Cullen W.R., Aposhian H.V., Zheng B. Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem. 2000, 72:5172-5177.
20. Le X.C., Ma M., Cullen W.R., Aposhian H.V., Lu X., Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ. Health Perspect. 2000, 108:1015-1018.
21. Livak K. ABI Prism 7700 Sequence Detection System, User Bulletin 2, 1997, PE Applied Biosystems.
22. Loffredo C.A., Aposhian H.V., Cebrian M.E., Yamauchi H., Silbergeld E.K. Variability in human metabolism of arsenic. Environ. Res. 2003, 92:85-91.
23. Neda S., Ute M.M., Branko B., Arijana Z., Bojan J. p53 mutations as fingerprints for aristolochic acid-an environmental carcinogen in endemic (Balkan) nephropathy. Mutat. Res. 2009, 663:1-6.
24. Sarah R.M., Rebecca N., Korry J.H., William T.S. Exposure to monomethylarsonous acid (MMAIII) leads to altered selenoprotein synthesis in a primary human lung cell model. Toxicol. Appl. Pharmacol. 2009, 239:130-136.
25. Smith T.J., Crecelius E.A., Reading J.C. Airborne arsenic exposure and excretion of methylated arsenic compounds. Environ. Health Perspect. 1977, 19:89-93.
26. Sofia K., Tania A., Athena K., Alexandra A., Theodora K., Elisavet G., Dimitris K., et al. Non-CpG cytosine methylation of p53 exon 5 in non-small cell lung carcinoma. Lung Cancer 2005, 50:299-307.
27. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci. 2000, 910:121-137.
28. Susan S.W. Biological consequences of free radical-damaged DNA bases. Free Radic Biol. Med. 2002, 33:1-14.
29. Thomas D.J., Waters S.B., Styblo M. Elucidating the pathway for arsenic methylation. Toxicol Appl Pharmacol 2004, 198:319-326.
30. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., Devesa V., Styblo M. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. (Maywood) 2007, 232:3-13.
31. Vahter M. Methylation of inorganic arsenic in different mammalian species and population groups. Sci. Prog. 1999, 82:69-88.
32. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002, 181-182:211-217.
33. Valenzuela O.L., Boria-Aburto V.H., Garcia-Vargas G.G., Cruz-Gonzalez M.B., Garcia-Montalvo E.A., Calderon-Aranda E.S., et al. Urinary trivalent methyllated arsenic species in a population thronically exposed to inorganic As. Environ. Health. Perspect. 2005, 113:250-254.
34. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
35. Waters S.B., Devesa-Perez V., Del Razo L.M., Styblo M., Thomas D.J. Endogenous reductants support catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem. Res. Toxicol. 2004, 17:404-409.
36. Weihua W., Wangjun C., Lin L., Jun Y., Xufang G., Jinghua W., Zhengchang H., et al. Increased damage of exon 5 of p53 gene in workers from an arsenic plant. Mutat. Res. 2008, 643:36-40.
37. Wnek S.M., Medeiros M.K., Eblin K.E., Gandolfi A.J. Persistence of DNA damage following exposure of human bladder cells to chronic monomethylarsonous acid. Toxicol. Appl. Pharmacol. 2009, 241:202-209.
38. Yamachi H., Yamamura Y. Metabolism and excretion of orally administered dimethylarsinic acid in the hamster. Toxicol. Appl. Pharmacol. 1984, 174:134-140.
39. Yen-Ching C., Huey-Jenny J.S., Yu-Liang L.G., Yu-Mei H., Thhomas J.S. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Cause. Control. 2003, 14:303-310.
40. Yen-Ching C., Huey-Jen J.S., Yu-Liang L.G., Andres E.H., David C.C. Interaction between environmental tobacco smoke and arsenic methylation ability on the risk of bladder cancer. Cancer Causes and Control 2005, 16:75-81.
41. Yung-Kai H., Chin-Hsiao T., Ya-Li H., Mo-Hsiung Y., Chien-Jen C., Yu-Mei H. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol. Appl. Pharmacol. 2007, 218:135-142.
42. Zuzana D., Felecia S.W., Anne W.H., David J.T., Miroslav S. Interspecies differences in metabolism of arsenic by cultured primary hepatocytes. Toxicol. Appl. Pharmacol. 2010, 245:47-56.